The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 333:259 July 27, 1995 Number 4
NextNext

Recombinant Tissue Plasminogen Activator for Prosthetic Mitral-Valve Thrombosis

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
To the Editor: The reported incidence of thrombosis of prosthetic mitral or aortic valves ranges from 0.03 to 4.3 percent per year.1 Thrombectomy or valve replacement is the conventional treatment for this condition, with an associated mortality rate ranging from 4.7 to 20 percent.2 Thrombolysis is emerging as a promising alternative to surgery, particularly in critically ill patients, with a success rate ranging from 75 to 83 percent.1 Most patients in published series have been treated with infusions of streptokinase or urokinase for 12 to 24 hours.1,3,4 Not all obstructed valves respond to thrombolysis, however. The valve obstruction is due . . . [Full Text of this Article]

References



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.